Key Highlights
- USD 302.77 was the Cigna Group (NYSE:CI) price per published market data (October 16, 2026 intraday), up 1.33% and 2.8% below the 52-week high of USD 311.34, own arithmetic. The 52-week low is USD 239.51 and market capitalization is USD 80.01 billion.
- USD 30.45 is the floor of the 2026 adjusted EPS outlook, raised by USD 0.10 on July 30, 2026 and reaffirmed at the September 30 investor day. The intraday price is 9.9 times that floor, own arithmetic on two published numbers.
- USD 71.7 billion was second quarter 2026 revenue, up 7%, per the company release dated July 30, 2026. Adjusted EPS was USD 7.78 against USD 7.20, up 8.1% by own arithmetic, while the Cigna Healthcare medical care ratio rose to 84.5% from 83.2%.
- USD 342.29 is the average analyst price target per published market data, 13.1% above the intraday price by own arithmetic. Piper Sandler raised its target to USD 370 from USD 346, while Evercore ISI holds In Line with a USD 290 target.
Price Action and Valuation Context
Cigna Group (NYSE:CI) closed at USD 298.81 on October 15, 2026, up 3.19%, and traded at USD 302.77 intraday on October 16. No company release explains the October 15 move. It followed the October 9 Star Ratings news at Humana (NYSE:HUM). The valuation is low against the market: published market data show a trailing P/E of 12.36 and a forward P/E of 9.41. The RSI of 73.2 is above the 70 overbought threshold.
Earnings and Guidance Drivers
Per the company release dated July 30, 2026, second quarter shareholders' net income was USD 1.66 billion, or USD 6.29 per share. Evernorth adjusted revenue rose 6% to USD 61.5 billion while its adjusted income fell 2% to USD 1.66 billion. Pharmacy Benefit Services income dropped 27% to USD 609 million, offset by a 22% gain in Specialty and Care Services. Cigna Healthcare adjusted income rose 17% to USD 1.28 billion. At the September 30 investor day it introduced its Lead to One strategy and a USD 3 billion multi-year modernization program.
Analyst Positioning and Risks
Raymond James rates the shares Outperform with a USD 320 target, Baird raised its target to USD 362, and Guggenheim to USD 361. The 2026 outlook for the Cigna Healthcare medical care ratio is 83.7% to 84.7%, so the second quarter 84.5% leaves limited room if medical costs accelerate. Rebate regulation pressures Evernorth margins. A reported USD 45 EPS floor from the investor day was not independently confirmed in the filings reviewed. Next earnings are on November 5, 2026.
Where Things Stand
Cigna Group (NYSE:CI) sits within a few percentage points of its high because earnings have been raised, not because the multiple has expanded. At 9.9 times the USD 30.45 floor, the market assigns a modest multiple to a company that lifted its outlook on July 30 and kept it on September 30. Against that, the medical care ratio is rising and the pharmacy benefit profit fell 27% in the second quarter. The 2.8% gap to USD 311.34 leaves little cushion if the RSI of 73.2 reverses. The next catalyst is the third quarter release on November 5, 2026.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...